GlassScriptPhysician profile
Ciomara L Hernandez
NPI 1144371071
$2,087.43
in general payments reported to CMS, 2019-2025
17 companies · $814 in 2025
The $814 reported for 2025 was more than what 83% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $24.81 · 2022: $216 · 2023: $520 · 2024: $394 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $479.16 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $414.67 | 2020-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Alkermes, INC. | $281.48 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $180.85 | 2019-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $100.25 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $93.82 | 2019 | |
| Neurocrine Biosciences, INC. | $92.10 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $90.97 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.29 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $57.45 | 2022-2024 | Invega Sustenna |
| Indivior INC. | $49.83 | 2022-2023 | Perseris |
| Janssen Scientific Affairs, LLC | $42.35 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $37.67 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $26.84 | 2022 | |
| Acadia Pharmaceuticals INC | $20.69 | 2024 | Nuplazid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.51 | 2025 | Abilify Maintena |
| Luye Pharma (USA) LTD. | $17.50 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciomara Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.